

TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE



FISCAL NOTE

SB 1020 - HB 1501

February 16, 2023

SUMMARY OF BILL: Requires, prior to issuing an initial prescription for a Schedule II controlled substance or another opioid pain reliever, and again prior to issuing a third prescription, a prescribing healthcare practitioner to discuss with the patient or patient's parent or guardian certain risks associated with the drugs being prescribed. Requires the practitioner to make note of such discussion in the patient's medical record. Exempts patients who are currently being treated for cancer, receiving hospice care, or who are residents of a long-term care facility. Does not apply to medications that are prescribed for use in the treatment of substance abuse or opioid dependence.

FISCAL IMPACT:

NOT SIGNIFICANT

Assumptions:

- The proposed legislation will not have a significant impact on the procedures or policies of the Department of Health or health-related boards.
- Any fiscal impact to state and local government is estimated to be not significant.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in black ink that reads "Krista Lee Carsner".

Krista Lee Carsner, Executive Director

/ch

SB 1020 - HB 1501